Your browser doesn't support javascript.
loading
Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado: characterizing enhancement and adverse reactions using mixed methods.
Piercey, Cianna J; Hetelekides, Eleftherios; Karoly, Hollis C.
Afiliación
  • Piercey CJ; Department of Psychology, Colorado State University, Fort Collins, CO, 80521, USA. Cianna.Piercey@colostate.edu.
  • Hetelekides E; Department of Psychology, Colorado State University, Fort Collins, CO, 80521, USA.
  • Karoly HC; Department of Psychology, Colorado State University, Fort Collins, CO, 80521, USA.
J Cannabis Res ; 6(1): 29, 2024 Jul 11.
Article en En | MEDLINE | ID: mdl-38992787
ABSTRACT

BACKGROUND:

Most studies examining the simultaneous use of cannabis with other drugs have focused on cannabis and alcohol, with fewer studies examining simultaneous use of cannabis with other drugs. The United States is currently experiencing an upward trend in psychedelic use and there is an increasing need to characterize cannabis and psychedelic drug interactions to best inform public health recommendations. MATERIALS AND

METHODS:

A mixed methods field study design was used to survey participants (N = 128) on their lifetime co-use of cannabis with other drugs. Participants who reported lifetime co-use of cannabis and psychedelics (N = 63) were then asked open-ended questions about their most recent simultaneous co-use experience (i.e., how cannabis enhanced their psychedelic experience and whether they experienced any adverse reactions). We conducted a thematic analysis of responses describing how cannabis enhanced the psychedelic experience (N = 54). However, due to low response rate for participants reporting an adverse reaction (N = 7, 11.1%), responses to this question were not analyzed thematically and are instead presented individually.

RESULTS:

Themes included tension reduction and balancing of drug effects (N = 27, 50%), enhancement to psychological processes (N = 11, 20.4%), intensified psychedelic drug effects (N = 12, 22.2%), enhanced psychedelic come-down experience (N = 8, 14.8%), and overall ambiguous enhancement (N = 7, 13%). Among participants reporting an adverse reaction, individual responses included increased anxiety and intensity of the experience, decreased sociability, increased negative affect, sleepiness, disassociation, and confusion.

CONCLUSION:

Additional research is warranted to better characterize cannabis and psychedelic drug interactions to best inform public health recommendations.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Cannabis Res Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Cannabis Res Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos